Stay updated on M7824 and Eribulin in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the M7824 and Eribulin in Metastatic TNBC Clinical Trial page.

Latest updates to the M7824 and Eribulin in Metastatic TNBC Clinical Trial page
- Check3 days agoChange DetectedLocations section now lists Texas as a study site, replacing the prior Texas Locations listing. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed. No changes to study details or page content are evident.SummaryDifference0.1%

- Check40 days agoChange DetectedRemoved the government funding status notice from the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check61 days agoChange DetectedThe study record now indicates termination of the trial due to sponsor decision, with updated completion and enrollment dates.SummaryDifference0.4%

- Check82 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

- Check90 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to M7824 and Eribulin in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 and Eribulin in Metastatic TNBC Clinical Trial page.